Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity
Altimmune(US:ALT) Seeking Alphaยท2025-05-29 14:25Altimmune Inc. ( ALT ) has an upcoming readout from the IMPACT phase 2b study of pemvidutide in metabolic dysfunction-associated steatohepatitis [MASH]. I rated ALT a buy in December 2024, based on the idea that pemvidutide's profile and ALT's valuationScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analys ...